Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease

Abstract Mesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Satohiro Matsumoto, Hirosato Mashima
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a50c4d8aa4dc4df286985a54519ff870
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a50c4d8aa4dc4df286985a54519ff870
record_format	dspace
spelling	oai:doaj.org-article:a50c4d8aa4dc4df286985a54519ff8702021-12-02T13:58:12ZMesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease10.1038/s41598-020-79207-z2045-2322https://doaj.org/article/a50c4d8aa4dc4df286985a54519ff8702020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79207-zhttps://doaj.org/toc/2045-2322Abstract Mesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 and March 2020, 33 diagnosed with mesalazine allergy (43 episodes) were included, and their clinical manifestations were evaluated. For ten patients undergoing desensitization therapy, therapeutic outcomes were evaluated. The incidence of mesalazine allergy was 4.8%. The time from the start of oral medication to allergy onset was 10 ± 5 days for the first allergic attack and 2 ± 1 days for the second and subsequent allergic attacks. The observed clinical symptoms included fever (93%), diarrhea (26%), abdominal pain (23%), and bloody stool (12%). Drug-induced lymphocyte stimulation test was performed in 85% of the patients (28/33), and the sensitivity was 51%. Desensitization therapy with a time-dependent mesalazine granule formulation was successful in nine of the ten patients (90%), allowing them to receive 2000 mg or more of the drug. Fever was a common allergic symptom, and its presence appeared to be useful for distinguishing mesalazine allergy from exacerbation of the primary disease. Desensitization therapy was useful in patients with mesalazine allergy.Satohiro MatsumotoHirosato MashimaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-7 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Satohiro Matsumoto Hirosato Mashima Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
description	Abstract Mesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 and March 2020, 33 diagnosed with mesalazine allergy (43 episodes) were included, and their clinical manifestations were evaluated. For ten patients undergoing desensitization therapy, therapeutic outcomes were evaluated. The incidence of mesalazine allergy was 4.8%. The time from the start of oral medication to allergy onset was 10 ± 5 days for the first allergic attack and 2 ± 1 days for the second and subsequent allergic attacks. The observed clinical symptoms included fever (93%), diarrhea (26%), abdominal pain (23%), and bloody stool (12%). Drug-induced lymphocyte stimulation test was performed in 85% of the patients (28/33), and the sensitivity was 51%. Desensitization therapy with a time-dependent mesalazine granule formulation was successful in nine of the ten patients (90%), allowing them to receive 2000 mg or more of the drug. Fever was a common allergic symptom, and its presence appeared to be useful for distinguishing mesalazine allergy from exacerbation of the primary disease. Desensitization therapy was useful in patients with mesalazine allergy.
format	article
author	Satohiro Matsumoto Hirosato Mashima
author_facet	Satohiro Matsumoto Hirosato Mashima
author_sort	Satohiro Matsumoto
title	Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
title_short	Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
title_full	Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
title_fullStr	Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
title_full_unstemmed	Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
title_sort	mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/a50c4d8aa4dc4df286985a54519ff870
work_keys_str_mv	AT satohiromatsumoto mesalazineallergyandanattemptatdesensitizationtherapyinpatientswithinflammatoryboweldisease AT hirosatomashima mesalazineallergyandanattemptatdesensitizationtherapyinpatientswithinflammatoryboweldisease
_version_	1718392218912292864

Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease

Ejemplares similares